Latina, Italy – 9 October 2020 – BSP Pharmaceuticals, a CDMO focused on the manufacturing of Anticancer and innovative drugs, has announced that the program for the ongoing expansion started in 2018 and aimed to open new capacity for Non-Cytotoxic products, has been speeded up and will be completed by 2023, three years in advance versus the original plan.
The project includes the installation of 6 filling lines, for liquid and lyophilized injectable products plus the implementation of all the ancillary services, including dedicated utilities, additional warehouse and new development laboratories.
The first two lines will be in operation starting from mid 2021 and the other four will be released within the following two years.
Starting capacity will be 12.7 million vials per annum and will be increased to 44.5 million by the end of 2023 , when the full project will be completed.
The new facility will operate a world class, full contained technology, and will be available for small and large molecules DP manufacturing. This plant will handle IMMUNO-ONCOLOGY drugs (mAbs, checkpoint inhibitors, synthetic vaccines), IMMUNOTHERAPY drugs, as well as other INNOVATIVE products with the objective to continue supporting innovators in a wide range of therapeutic indications.
Our goal is to elevate collaboration to strategic partnership, meeting customer’s needs without exposing them to inconvenient situations, maintaining a solid financial position that never compromises business continuity, paying great attention to the environment , health and safety on whatever we are doing.
BSP Pharmaceuticals is a CDMO providing development, manufacturing and analytical services for innovative small and large molecules. Capabilities can cover a wide range of batch sizes providing flexibility to sustain preclinical, clinical and commercial manufacturing. Operating a world class technology, BSP can offer full contained technology to manage High Potent APIs with OEL up to < 10ng/m3 and suitable for Biologics including mAbs, ADCs, synthetic peptides for Oncology and Non-Oncology therapies. New expansion will also open capacity to handle IMMUNO-ONCOLOGY drugs (mAbs, checkpoint inhibitors, synthetic vaccines), IMMUNOTHERAPY drugs, as well as other INNOVATIVE products with the objective to continue supporting innovators in a wide range of therapeutic indications.
BSP Pharmaceuticals is located in Latina, Italy.
For more information, visit http://www.bsppharmaceuticals.com/